Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2015) Xavier Pivot et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer: Evolution Within a Lifetime

(2014) Marco Gerlinger et al.   Annual Review of Genetics

Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study

(2014) Aki Morikawa et al.   NEURO-ONCOLOGY

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

(2012) Thomas Bachelot et al.   LANCET ONCOLOGY

Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

(2011) A. M. Brufsky et al.   CLINICAL CANCER RESEARCH

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

(2011) Kunal S. Taskar et al.   PHARMACEUTICAL RESEARCH

Metastatic Behavior of Breast Cancer Subtypes

(2010) Hagen Kennecke et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

(2008) J. R. Molina et al.   CLINICAL CANCER RESEARCH

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)

(2008) J. W. Polli et al.   DRUG METABOLISM AND DISPOSITION